{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-026142","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.996646+00:00","generated_at":"2026-05-24T10:11:25.766167+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TELA Bio reports Q4 revenue $17.6M (+4% YoY); guides FY2025 revenue $85-88M (+23-27%)","bullets":["FY2024 revenue $69.3M (+19% YoY); Q4 revenue $17.6M (+4% YoY) missed expectations due to transient disruptions.","FY2024 net loss narrowed to $37.8M from $46.7M in 2023; Q4 net loss $9.2M vs $12.9M a year ago.","FY2025 revenue guidance $85-88M (23-27% growth); Q1 2025 revenue expected $17-18M (2-8% growth).","Operating expenses step down Q3 to Q4; management targets 2025 OpEx flat vs 2024.","OviTex IHR product for inguinal hernia repair launched mid-April 2024, sold over 1,200 units in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-026142","json":"https://secwatch.observer/filing/0001104659-25-026142.json","markdown":"https://secwatch.observer/filing/0001104659-25-026142.md","text":"https://secwatch.observer/filing/0001104659-25-026142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925026142/0001104659-25-026142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925026142/tm259858d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:11:25.766167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}